Literature DB >> 26598973

The burden of disease attributable to cannabis use in Canada in 2012.

Sameer Imtiaz1,2, Kevin D Shield1,2, Michael Roerecke1,3, Joyce Cheng1,4, Svetlana Popova1,2,3,5, Paul Kurdyak1,4,6, Benedikt Fischer1,6,7, Jürgen Rehm1,2,3,6,8.   

Abstract

BACKGROUND AND AIMS: Cannabis use is associated with several adverse health effects. However, little is known about the cannabis-attributable burden of disease. This study quantified the age-, sex- and adverse health effect-specific cannabis-attributable (1) mortality, (2) years of life lost due to premature mortality (YLLs), (3) years of life lost due to disability (YLDs) and (4) disability-adjusted life years (DALYs) in Canada in 2012.
DESIGN: Epidemiological modeling.
SETTING: Canada. PARTICIPANTS: Canadians aged ≥ 15 years in 2012. MEASUREMENTS: Using comparative risk assessment methodology, cannabis-attributable fractions were computed using Canadian exposure data and risk relations from large studies or meta-analyses. Outcome data were obtained from Canadian databases and the World Health Organization. The 95% confidence intervals (CIs) were computed using Monte Carlo methodology.
FINDINGS: Cannabis use was estimated to have caused 287 deaths (95% CI = 108, 609), 10,533 YLLs (95% CI = 4760, 20,833), 55,813 YLDs (95% CI = 38,175, 74,094) and 66,346 DALYs (95% CI = 47,785, 87,207), based on causal impacts on cannabis use disorders, schizophrenia, lung cancer and road traffic injuries. Cannabis-attributable burden of disease was highest among young people, and males accounted for twice the burden than females. Cannabis use disorders were the most important single cause of the cannabis-attributable burden of disease.
CONCLUSIONS: The cannabis-attributable burden of disease in Canada in 2012 included 55,813 years of life lost due to disability, caused mainly by cannabis use disorders. Although the cannabis-attributable burden of disease was substantial, it was much lower compared with other commonly used legal and illegal substances. Moreover, the evidence base for cannabis-attributable harms was smaller.
© 2015 Society for the Study of Addiction.

Entities:  

Keywords:  Burden of disease; Canada; cannabis; comparative risk assessment; disability-adjusted life years; marijuana; mortality; years of life lost due to disability; years of life lost due to premature mortality

Mesh:

Year:  2016        PMID: 26598973     DOI: 10.1111/add.13237

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  29 in total

1.  Access to cannabis retail stores across Canada 6 months following legalization: a descriptive study.

Authors:  Daniel T Myran; Catherine R L Brown; Peter Tanuseputro
Journal:  CMAJ Open       Date:  2019-08-13

2.  Legalize marijuana without the smoke.

Authors:  Robert Schwartz
Journal:  CMAJ       Date:  2017-01-30       Impact factor: 8.262

Review 3.  Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations.

Authors:  Benedikt Fischer; Cayley Russell; Pamela Sabioni; Wim van den Brink; Bernard Le Foll; Wayne Hall; Jürgen Rehm; Robin Room
Journal:  Am J Public Health       Date:  2017-06-23       Impact factor: 9.308

4.  Vaporizing cannabis through e-cigarettes: Prevalence and socio-demographic correlates among Ontario high school students.

Authors:  George Mammen; Jürgen Rehm; Sergio Rueda
Journal:  Can J Public Health       Date:  2016-10-20

5.  Assessing the public health impact of cannabis legalization in Canada: core outcome indicators towards an 'index' for monitoring and evaluation.

Authors:  Benedikt Fischer; Cayley Russell; Jürgen Rehm; Pamela Leece
Journal:  J Public Health (Oxf)       Date:  2019-06-01       Impact factor: 2.341

6.  Thinking Beyond Legalization: The Case for Expanding Evidence-Based Options for Cannabis Use Disorder Treatment in Canada.

Authors:  Didier Jutras-Aswad; Bernard Le Foll; Julie Bruneau; T Cameron Wild; Evan Wood; Benedikt Fischer
Journal:  Can J Psychiatry       Date:  2018-07-22       Impact factor: 4.356

7.  Is the medical use of cannabis a therapeutic option for children?

Authors:  Michael J Rieder
Journal:  Paediatr Child Health       Date:  2016 Jan-Feb       Impact factor: 2.253

8.  Daily, but not occasional, cannabis use is selectively associated with more impulsive delay discounting and hyperactive ADHD symptoms in binge-drinking young adults.

Authors:  Tashia Petker; Mark Ferro; Michael Van Ameringen; James Murphy; James MacKillop
Journal:  Psychopharmacology (Berl)       Date:  2021-02-27       Impact factor: 4.530

9.  Legalizing and Regulating Marijuana in Canada: Review of Potential Economic, Social, and Health Impacts.

Authors:  Mohammad Hajizadeh
Journal:  Int J Health Policy Manag       Date:  2016-08-01

10.  The Effects of Acute Cannabis Use on Nontraffic Injury Risk: Reviewing the Available Literature and Identifying Ways Forward.

Authors:  Gabriel Andreuccetti; Yu Ye; Jaewook Kang; Rachael Korcha; Jane A Witbrodt; Heraclito B Carvalho; Cheryl J Cherpitel
Journal:  Contemp Drug Probl       Date:  2017-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.